Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection

Journal of Hepatology

Volumn 46, Issue 3, 2007, Pages 372-380

  Schott, Eckart ^a   Witt, Heiko ^a   Hinrichsen, Holger ^b   Neumann, Konrad ^a   Weich, Viola ^a   Bergk, Alexandra ^a   Halangk, Juliane ^a   Müller, Tobias ^a   Tinjala, Sebastian ^a   Puhl, Gero ^a   Neuhaus, Peter ^a   Wiedenmann, Bertram ^a   Berg, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Co stimulation; Interferon ; Sex specific trait; T cell immunology

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; RIBAVIRIN;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; SEX CHARACTERISTICS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33846631307     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.09.011     Document Type: Article

References (40)

1. Cohen J. The scientific challenge of hepatitis C. Science 285 (1999) 26-30
2. Yoshioka K., Higashi Y., Yamada M., Aiyama T., Takayanagi M., Tanaka K., et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 15 (1995) 57-62
3. Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandhi R.T., et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 76 (2002) 12584-12595
4. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76 (2002) 6104-6113
5. Cucchiarini M., Kammer A.R., Grabscheid B., Diepolder H.M., Gerlach T.J., Gruner N., et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 203 (2000) 111-123
6. Diepolder H.M., Gerlach J.T., Zachoval R., Hoffmann R.M., Jung M.C., Wierenga E.A., et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71 (1997) 6011-6019
7. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 (1996) 706-714
8. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 (2000) 1499-1512
9. Wertheimer A.M., Miner C., Lewinsohn D.M., Sasaki A.W., Kaufman E., and Rosen H.R. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37 (2003) 577-589
10. Vertuani S., Bazzaro M., Gualandi G., Micheletti F., Marastoni M., Fortini C., et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 32 (2002) 144-154
11. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., and Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30 (1999) 526-530
12. Mueller T., Mas-Marques A., Sarrazin C., Wiese M., Halangk J., Witt H., et al. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 41 (2004) 652-658
13. Wasmuth H.E., Werth A., Mueller T., Berg T., Dietrich C.G., Geier A., et al. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology 40 (2004) 327-334
14. Hijikata M., Mishiro S., Miyamoto C., Furuichi Y., Hashimoto M., and Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology 44 (2001) 379-382
15. Yee L.J., Perez K.A., Tang J., van Leeuwen D.J., and Kaslow R.A. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 187 (2003) 1264-1271
16. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (1995) 985-988
17. Deichmann K., Heinzmann A., Bruggenolte E., Forster J., and Kuehr J. An Mse I RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 225 (1996) 817-818
18. Nistico L., Buzzetti R., Pritchard L.E., Van der Auwera B., Giovannini C., Bosi E., et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 5 (1996) 1075-1080
19. Kouki T., Sawai Y., Gardine C.A., Fisfalen M.E., Alegre M.L., and DeGroot L.J. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165 (2000) 6606-6611
20. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511
21. Aguilar F., Torres B., Sanchez-Roman J., Nunez-Roldan A., and Gonzalez-Escribano M.F. CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol 64 (2003) 936-940
22. Parks C.G., Hudson L.L., Cooper G.S., Dooley M.A., Treadwell E.L., St Clair E.W., et al. CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. Lupus 13 (2004) 784-791
23. Bouqbis L., Izaabel H., Akhayat O., Perez-Lezaun A., Calafell F., Bertranpetit J., et al. Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun 4 (2003) 132-137
24. Agarwal K., Czaja A.J., Jones D.E., and Donaldson P.T. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 31 (2000) 49-53
25. Agarwal K., Jones D.E., Daly A.K., James O.F., Vaidya B., Pearce S., et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 32 (2000) 538-541
26. Djilali-Saiah I., Ouellette P., Caillat-Zucman S., Debray D., Kohn J.I., and Alvarez F. CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 62 (2001) 1356-1362
27. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 (2000) 578-582
28. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372-374
29. Stephens M., and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73 (2003) 1162-1169
30. Thio C.L., Mosbruger T.L., Kaslow R.A., Karp C.L., Strathdee S.A., Vlahov D., et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 78 (2004) 11258-11262
31. Teft W.A., Kirchhof M.G., and Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 8 (2005) 8
32. Maurer M., Loserth S., Kolb-Maurer A., Ponath A., Wiese S., Kruse N., et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54 (2002) 1-8
33. Atabani S.F., Thio C.L., Divanovic S., Trompette A., Belkaid Y., Thomas D.L., et al. Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol 35 (2005) 2157-2162
34. Schuppan D., Krebs A., Bauer M., and Hahn E.G. Hepatitis C and liver fibrosis. Cell Death Differ 10 Suppl. 1 (2003) S59-S67
35. Ratziu V., Heurtier A., Bonyhay L., Poynard T., and Giral P. Review article: an unexpected virus-host interaction - the hepatitis C virus-diabetes link. Aliment Pharmacol Ther 22 Suppl. 2 (2005) 56-60
36. Kast R.E. Predominance of autoimmune and rheumatic diseases in females. J Rheumatol 4 (1977) 288-292
37. Xie Y., Xu D.Z., Lu Z.M., Luo K.X., Jia J.D., Wang Y.M., et al. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary Pancreat Dis Int 4 (2005) 213-219
38. Sharp A., Robinson D., and Jacobs P. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet 107 (2000) 343-349
39. Reddy J., Waldner H., Zhang X., Illes Z., Wucherpfennig K.W., Sobel R.A., et al. Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J Immunol 175 (2005) 5591-5595
40. Marder B.A., Schroppel B., Lin M., Schiano T., Parekh R., Tomer Y., et al. The impact of costimulatory molecule gene polymorphisms on clinical outcomes in liver transplantation. Am J Transplant 3 (2003) 424-431